Colorectal cancer is the third most common malignancy worldwide and the second leading cause of cancer-related mortality.1 The liver is the most frequent site of metastatic spread. While surgical resection is the only potentially curative option for colorectal liver metastases, many patients present with disease that is technically unresectable or associated with unfavorable oncological features.2–4 Permanently unresectable liver-only metastatic colorectal cancer has therefore long been considered a palliative condition, treated exclusively with systemic chemotherapy, with 5-year survival rarely exceeding 10–15%.
Journal of Hepatology published a clinical update in Research Highlights on 11 Feb 2026.
The item focuses on One year after the TransMet trial: Transplant oncology at a turning point.
Review the original article for the full source wording and details.